Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry

(2012) M. K. Kvamme et al.   RHEUMATOLOGY

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

(2011) D. T. Felson et al.   ANNALS OF THE RHEUMATIC DISEASES

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints

(2011) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

(2011) David T. Felson et al.   ARTHRITIS AND RHEUMATISM

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) M. Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Does Clinical Remission Lead to Normalization of EQ-5D in Patients with Rheumatoid Arthritis and Is Selection of Remission Criteria Important?

(2010) L. LINDE et al.   JOURNAL OF RHEUMATOLOGY

Validity of the work productivity and activity impairment questionnaire - general health version in patients with rheumatoid arthritis

(2010) Wei Zhang et al.   ARTHRITIS RESEARCH & THERAPY

Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment

(2009) D. Aletaha et al.   ARTHRITIS AND RHEUMATISM

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

(2008) J S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

(2008) Edward Keystone et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET